01—Abstract
Summary
Summary of the 10-Q/A filed August 8, 2003. Cited figures are marked; the original filing is the authoritative source.
Ecolab Inc. (ECL) reported a strong first quarter for 2003, demonstrating significant year-over-year growth.
Net sales increased by 11% to $875.8 milliona, driven by organic growth, acquisitions, and a favorable currency translation impact. The company's profitability saw a substantial improvement, with net income rising 58% to $55.3 million, translating to a diluted EPS of $0.42, up from $0.27 in the prior year. This earnings growth was bolstered by improved gross profit margins due to product mix and cost reduction efforts, alongside effective cost controls in selling, general, and administrative expenses.
Comparisons to the prior year's first quarter were impacted by significant one-time events in 2002, including restructuring charges and a curtailment gain, which skewed profitability metrics. For 2003, Ecolab is realizing cost savings from previous restructuring initiatives, with a portion being reinvested into the business to fuel growth.
The company also saw increased investments in sales and service, along with higher healthcare costs. Ecolab maintained a solid financial position, with total assets increasing and a healthy debt-to-capitalization ratio.
02—Key points
Key Highlights
- Consolidated net sales increased 11% to $875.8 million for Q1 2003 compared to Q1 2002.
- Net income grew significantly by 58% to $55.3 million, with diluted EPS rising to $0.42 from $0.27.
- Gross profit margin improved to 50.8% in Q1 2003 from 49.6% in Q1 2002 (50.3% excluding restructuring charges).
- Selling, general, and administrative expenses as a percentage of sales increased slightly to 39.3% from 38.8%, attributed to acquisitions and investments.
- The company realized $7.5 million in restructuring savings in Q1 2003, with expectations of $25-$30 million pre-tax annual savings.
- Total assets increased to $3.01 billion, driven by acquisitions and currency exchange rate effects.
- The company reported adopting SFAS No. 142, discontinuing amortization of goodwill and indefinite-lived intangibles, and took a $4.0 million impairment charge in Q1 2002 related to this adoption.
03—Questions
Frequently Asked Questions
What were the main drivers of Ecolab's sales growth in the first quarter of 2003?
Ecolab's net sales increased by 11% year-over-year to $875.8 million. This growth was driven by a combination of factors including organic growth from aggressive new account sales, successful new product introductions, improved service initiatives, and the positive impact of business acquisitions and favorable foreign currency translation effects.
How did the company's profitability change in the first quarter of 2003 compared to 2002?
Profitability saw a substantial improvement. Net income increased by 58% to $55.3 million, leading to a diluted EPS of $0.42, up from $0.27 in the prior year. This improvement was due to higher sales, an improved gross profit margin (50.8% vs. 49.6%), and effective cost controls. The comparison was also aided by the absence of significant one-time charges that impacted the prior year's first quarter.
What is the impact of the adoption of SFAS No. 142 on Ecolab's financial statements?
Ecolab adopted SFAS No. 142 effective January 1, 2002, which discontinued the amortization of goodwill and indefinite-lived intangible assets. In the first quarter of 2002, the company recorded a non-cash impairment charge of $4.0 million related to this adoption, which negatively impacted the prior year's results. For 2003, this change means that goodwill is no longer amortized but is subject to periodic impairment testing.
Can you explain the 'Special Charges' mentioned in the report?
In the first quarter of 2002, Ecolab incurred significant special charges totaling $23.3 million related to restructuring and cost-saving actions, including global workforce reductions and facility closings, primarily for the integration of European operations. There was also a curtailment gain of $5.8 million related to postretirement healthcare benefit changes in the same period. These significant one-time items in Q1 2002 make the year-over-year comparison of Q1 2003 results more favorable due to their absence.
04—Continue